Zacks.com on MSN1d
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline ...
Yahoo1d
Puma commences Phase II trial of alisertib for breast cancer treatment
In this trial, alisertib will be assessed in conjunction with endocrine therapy for treating individuals having hormone ...
emjreviews.com6d
New Approach Offers Hope for Drug-Resistant Lung Cancer
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
Science Daily8d
How studying fruit flies can help us understand congenital defects
Researchers elucidated the molecular details of how Drosophila larval epidermal cells (LECs) undergo cell death in a controlled manner to regulate epithelial tissue remodeling. Specifically, lower ...
Medscape3d
When or Whether to Give Immunotherapy in Early Breast Cancer
Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...
Metropolis Healthcare unveils Key Findings from Molecular Genomics Study in honour of Lung Cancer Awareness Month
In observance of Lung Cancer Awareness Month this November, Metropolis Healthcare, one of India's leading and most reputed diagnostic chains, conducted a landmark seven-year research study (2015-2021) ...
AstraZeneca’s Tagrisso recommended for approval in EU by CHMP for certain NSCLC
Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...
News Medical on MSN4d
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy
Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...